FMP
Relmada Therapeutics, Inc.
RLMD
NASDAQ
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
0.363 USD
0.0102 (2.81%)
About
ceo
Dr. Sergio Traversa M.B.A., Pharm.D.
sector
Healthcare
industry
Biotechnology
website
https://www.relmada.comexchange
NASDAQ
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
CIK
0001553643
ISIN
US75955J4022
CUSIP
75955J402
Address
2222 Ponce de Leon Boulevard
Phone
786 629 1376
Country
US
Employee
20
IPO Date
Jun 20, 2014
Key Executives
